|Day Low/High||79.35 / 81.87|
|52 Wk Low/High||26.02 / 98.70|
Jim Cramer takes a look at Xilinx, AMD, CyberArk Software, NovoCure, Glu Mobile, Vermillion Energy, Cliffs Natural Resources and more.
The oncology company has had a strong run and all the technical signals indicate the move higher isn't over.
Jim Cramer says tariff delays could spur some trade-talks progress, and at least they keep the market bears at bay for a bit.
Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative commercial stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology company with a proprietary platform technology called Tumor Treating Fields, today announced that the...
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component NovoCure Ltd was identified as having a larger market cap than the smaller end of the S&P 500, for example F5 Networks, Inc. , according to The Online Investor.
Let's look at the charts and indicators in addition to following the fundamentals.
Jim Cramer says there may be more volatility ahead, but investors should know the U.S. still has the upper hand in the trade and currency disputes with China.
Jim Cramer takes a closer look at eBay, Citigroup, Funko, PayPal, Carnival Cruise Lines, Hain Celestial, Zynga and more.
Novocure (NASDAQ: NVCR) announced today that it will participate in three upcoming investor conferences.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ANIK, AXTA, EIX, FDC, HOMB, NVCR, PSEC Downgrades: F, MAS Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Novocure (NASDAQ: NVCR) today reported financial results for the three and six months ended June 30, 2019, highlighting a track record of execution, strengthening financial performance and an advancing clinical pipeline.
Novocure (NASDAQ: NVCR) today announced 10 oral presentations and a special session on Tumor Treating Fields at the 41st International Engineering in Medicine and Biology (EMB) Conference, July 23 through July 27, in Berlin.
Novocure (NASDAQ: NVCR) today announced the U.S Centers for Medicare & Medicaid Services (CMS) has established a 2019 monthly fee schedule amount for Optune.
Novocure (NASDAQ: NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have released a final local coverage determination (LCD) providing coverage of Optune for Medicare beneficiaries with newly...
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2019 on Thursday, July 25, 2019, before the U.
Novocure (NASDAQ: NVCR) today announced that the German Institute for Quality and Efficiency in Healthcare, or IQWiG, has published its rapid report concluding that, based on a review of Novocure's EF-14 phase 3 pivotal trial, patients with newly...
The oncology company already has risen significantly this year, but its charts indicate the rally could continue.
Jim Cramer weighs in on U.S. Steel, Insperity, NovoCure, Aqua America, Universal Display, Teva Pharmaceuticals, Marathon Petroleum and more.
Jim Cramer says investing can be fun and rewarding -- if you really understand what you own. But keep your eye on the Fed this week.
Novocure (NASDAQ: NVCR) announced today that Bill Doyle, Novocure's Executive Chairman, will participate in the Jefferies 2019 Global Healthcare Conference on June 4, 2019, in New York City.
Novocure (NASDAQ: NVCR) today announced that the U.S.
Novocure (NASDAQ: NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have issued a proposed local coverage determination (LCD ) that provides coverage of Tumor Treating Fields, or Optune, for...
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2019, highlighting continued revenue growth, an advancing clinical pipeline and a strong cash position.
Novocure (NASDAQ:NVCR) announced today that the International Journal of Radiation Oncology, Biology, Physics, known in the field as the Red Journal, has published the results of an EF-14 post-hoc analysis demonstrating that higher doses of Tumor Treating...
Jim Cramer says a dip ahead of earnings can be the best protection against a hammering when a stock comes in too hot.
Jim Cramer weighs in on Twilio, Aurora Cannabis, Levi's, Entergy, NovoCure, Marathon Petroleum, Zix, Party City and more.
Novocure (NASDAQ: NVCR) announced today the publication of its 2018 Annual Report featuring its vision, mission and values, employee stories and videos, business highlights and selected financial information.
The recipients of the AACR-Novocure Tumor Treating Fields research grants were announced on April 2 at the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.